drugset / Trial / NCT01759732

Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia

NCT01759732

Phase 2 Unknown 10 enrolled Asan Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Rationale: Fludarabine, cyclophosphamide, anti-thymocyte globulin and low-dose total body irradiation (LD-TBI) may induce the engraftment cross the immunologic barrier in the setting of HLA-haploidentical allogeneic hematopoietic cell transplantation. In addition, depletion of CD3 cells may contribute to prevent developing severe acute graft versus host disease (GVHD) in haploidentical transplantation. Purpose: Phase II trials to evaluate the efficacy of haploidentical stem cell transplantation with fixed dose of T cells after in vitro T cell depletion using CD3 monoclonal antibody for children with acquired severe aplastic anemia

Timeline

Start
2012-09
Primary completion
2014-12
Completion
2015-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic
Background Cyclophosphamide Other / unclassified 60 mg/kg Intravenous
Background Fludarabine Small molecule 40 mg/m2 Intravenous
Background filgrastim Protein / enzyme biologic